Information Letter on Halaven® (eribulin): Danger of dosing errors
2012.03.05
Active substance: eribulin
Danger of dosing errors due to the fact that the dose is stated differently in the EU compared to several other regions and in some publications.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN